Company intelligence / Profile preview

Myra Vision

Campbell, California, United Statesmyravision.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Myra Vision is developing the Calibreye™ System, a next-generation titratable aqueous shunt for personalized reduction of intraocular pressure (IOP) in patients with moderate to severe glaucoma. Initial results from a multi-center feasibility study presented at the 2025 American Glaucoma Society meeting showed significant reductions in IOP and medication use compared to baseline. The system allows non-invasive adjustment of outflow post-surgery for evolving patient needs.

Therapeutic areas: Ophthalmology
Modalities: DeviceNanotechnology-based device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Calibreye TGT Surgical System

Phase 1

Indications: Moderate to severe glaucoma

Beyond the preview

Go deeper on Myra Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myra Vision.

Explore the full profile